'Hypertensive nephrosclerosis' is a non-specific clinical diagnosis applied to non-diabetic patients, often those with recent African ancestry, who present with chronic kidney disease, low-level proteinuria and elevated blood pressure
Poorly controlled mild-to-moderate hypertension can contribute to arteriolar nephrosclerosis, a vascular lesion in the preglomerular arterioles that leads to glomerular ischaemia
Non-diabetic aetiologies of end-stage renal disease (ESRD), including those typically ascribed to essential hypertension, lupus nephritis, focal segmental glomerulosclerosis or HIV-associated nephropathy, aggregate in African American families
Patients in such multiplex families who lack an obvious initiating cause of nephropathy are often labelled as having 'hypertensive nephrosclerosis' after a cursory evaluation
Genetic breakthroughs demonstrate that inherited forms of glomerulosclerosis can present in a similar fashion to arteriolar nephrosclerosis; these renal-limited disorders secondarily elevate blood pressure
The presence of two apolipoprotein L1 gene (APOL1) renal-risk variants is powerfully associated with approximately 70% of non-diabetic glomerulosclerosis and up to 40% of all cases of ESRD in African Americans
Unrelated disease processes commonly occur in non-diabetic individuals with mild-to-moderate hypertension and low level or absent proteinuria who present with chronic kidney disease: primary glomerulosclerosis in those with recent African ancestry, and arteriolar nephrosclerosis with resultant glomerular ischaemia potentially related to hypertension and vascular disease risk factors in other cases. Unfortunately, nephrologists often indiscriminately apply a diagnosis of 'hypertensive nephrosclerosis' to patients in either scenario, which implies that the hypertension is causative of their renal disease. Although nephropathies that are associated with variants in the apolipoprotein L1 gene (APOL1) often cause secondarily elevated blood pressure, they belong to the spectrum of focal segmental glomerulosclerosis and are not initiated by systemic hypertension. Because genetic testing for APOL1 variants and other glomerulosclerosis-associated gene variants is available and can provide a precise definition of disease pathogenesis, we believe that the term 'hypertensive nephrosclerosis' should now be abandoned and replaced with either gene-based (for example, APOL1-associated) glomerulosclerosis or arteriolar nephrosclerosis. Precision medicine will be key to improving diagnostic accuracy in this field. Discrimination of these disparate disorders has the potential to eradicate primary forms of glomerulosclerosis that are associated with APOL1 renal-risk variants.
Your institute does not have access to this article
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Smith, S. R., Svetkey, L. P. & Dennis, V. W. Racial differences in the incidence and progression of renal diseases. Kidney Int. 40, 815–822 (1991).
Freedman, B. I., Iskandar, S. S. & Appel, R. G. The link between hypertension and nephrosclerosis. Am. J. Kidney Dis. 25, 207–221 (1995).
Freedman, B. I. & Murea, M. Target organ damage in African American hypertension: role of APOL1. Curr. Hypertens. Rep. 14, 21–28 (2012).
Kopp, J. B. Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder. Curr. Opin. Nephrol. Hypertens. 22, 266–272 (2013).
Skorecki, K. L. & Wasser, W. G. Hypertension-misattributed kidney disease in African Americans. Kidney Int. 83, 6–9 (2013).
Meyrier, A. Nephrosclerosis: a term in quest of a disease. Nephron 129, 276–282 (2015).
Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841–845 (2010).
Tzur, S. et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128, 345–350 (2010).
Freedman, B. I. et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J. Am. Soc. Nephrol. 21, 1422–1426 (2010).
Palmer, N. D. & Freedman, B. I. APOL1 and progression of nondiabetic nephropathy. J. Am. Soc. Nephrol. 24, 1344–1346 (2013).
Sadowski, C. E. et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J. Am. Soc. Nephrol. 26, 1279–1289 (2015).
Rule, A. D. et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann. Intern. Med. 152, 561–567 (2010).
Saran, R. et al. US Renal Data System 2014 Annual Data Report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 66, S1–S306 (2015).
Venkat-Raman, G. et al. New primary renal diagnosis codes for the ERA-EDTA. Nephrol. Dial. Transplant. 27, 4414–4419 (2012).
Klag, M. J. et al. Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 334, 13–18 (1996).
Castaneda, C. et al. Clinical decision support systems for improving diagnostic accuracy and achieving precision medicine. J. Clin. Bioinforma. 5, 4 (2015).
Kiryluk, K. et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 8, e1002765 (2012).
Shaffer, J. R. et al. Genetic markers for ancestry are correlated with body composition traits in older African Americans. Osteoporos. Int. 18, 733–741 (2007).
Ochs-Balcom, H. M. et al. Association of DXA-derived bone mineral density and fat mass with African ancestry. J. Clin. Endocrinol. Metab. 98, E713–E717 (2013).
Powe, C. E. et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N. Engl. J. Med. 369, 1991–2000 (2013).
Wassel, C. L. et al. Genetic ancestry is associated with subclinical cardiovascular disease in African-Americans and Hispanics from the multi-ethnic study of atherosclerosis. Circ. Cardiovasc. Genet. 2, 629–636 (2009).
Divers, J. et al. Admixture mapping of coronary artery calcified plaque in African Americans with type 2 diabetes mellitus. Circ. Cardiovasc. Genet. 6, 97–105 (2013).
Zarif, L. et al. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol. Dial. Transplant. 15, 1801–1807 (2000).
Perneger, T. V., Whelton, P. K., Klag, M. J. & Rossiter, K. A. Diagnosis of hypertensive end-stage renal disease: effect of patient's race. Am. J. Epidemiol. 141, 10–15 (1995).
Kramer, H. J., Nguyen, Q. D., Curhan, G. & Hsu, C. Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 289, 3273–3277 (2003).
Mak, S. K. et al. Clinical predictors of non-diabetic renal disease in patients with non-insulin dependent diabetes mellitus. Nephrol. Dial. Transplant. 12, 2588–2591 (1997).
Freedman, B. I. et al. Differential effects of MYH9 and APOL1 risk variants on FRMD3 association with diabetic ESRD in African Americans. PLoS Genet. 7, e1002150 (2011).
Davids, M. R., Marais, N. & Jacobs, J. C. South African Renal Registry Annual Report 2012. South African Renal Society [online], (2014).
Seedat, Y. K. & Brewster, L. M. What role does African ancestry play in how hypertensive patients respond to certain antihypertensive drug therapy? Expert. Opin. Pharmacother. 15, 159–161 (2014).
Rostand, S. G., Brown, G., Kirk, K. A., Rutsky, E. A. & Dustan, H. P. Renal insufficiency in treated essential hypertension. N. Engl. J. Med. 320, 684–688 (1989).
Narvarte, J., Prive, M., Saba, S. R. & Ramirez, G. Proteinuria in hypertension. Am. J. Kidney Dis. 10, 408–416 (1987).
Mujais, S. K., Emmanouel, D. S., Kasinath, B. S. & Spargo, B. H. Marked proteinuria in hypertensive nephrosclerosis. Am. J. Nephrol. 5, 190–195 (1985).
Harvey, J. M. et al. Renal biopsy findings in hypertensive patients with proteinuria. Lancet 340, 1435–1436 (1992).
Freedman, B. I., Iskander, S. S., Buckalew, V. M. Jr, Burkart, J. M. & Appel, R. G. Renal biopsy findings in presumed hypertensive nephrosclerosis. Am. J. Nephrol. 14, 90–94 (1994).
Tracy, R. P. & Bovill, E. G. Thrombosis and cardiovascular risk in the elderly. Arch. Pathol. Lab. Med. 116, 1307–1312 (1992).
Fogo, A. et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int. 51, 244–252 (1997).
Harrison, D. G. et al. Inflammation, immunity, and hypertension. Hypertension 57, 132–140 (2011).
Marcantoni, C., Ma, L. J., Federspiel, C. & Fogo, A. B. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int. 62, 172–180 (2002).
Larsen, C. P. et al. Histopathologic findings associated with APOL1 risk variants in chronic kidney disease. Mod. Pathol. 28, 95–102 (2014).
Hoy, W. E. et al. APOL1 risk alleles are associated with exaggerated age-related changes in glomerular number and volume in African-American adults: an autopsy study. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2014080768 (2015).
[No authors listed] The Australian therapeutic trial in mild hypertension: report by the Management Committee. Lancet 1, 1261–1267 (1980).
Neaton, J. D., Kuller, L. H., Wentworth, D. & Borhani, N. O. Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentration, and diastolic blood pressure among black and white males followed up for five years. Am. Heart J. 108, 759–769 (1984).
Textor, S. C. & Lerman, L. Renovascular hypertension and ischemic nephropathy. Am. J. Hypertens. 23, 1159–1169 (2010).
Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612 (2009).
Coresh, J., Astor, B. C., Greene, T., Eknoyan, G. & Levey, A. S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population. Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 41, 1–12 (2003).
Shulman, N. B. et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. Hypertension 13, I80–I93 (1989).
Anyaegbu, E. I., Shaw, A. S., Hruska, K. A. & Jain, S. Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease. Pediatr. Nephrol. 30, 983–989 (2015).
Ambrosius, W. T. et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin. Trials 11, 532–546 (2014).
Wright, J. T. Jr et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288, 2421–2431 (2002).
Agodoa, L. Y. et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285, 2719–2728 (2001).
Appel, L. J. et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N. Engl. J Med 363, 918–929 (2010).
Kopp, J. B. et al. Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS clinical trial. J. Am. Soc. Nephrol. 26, 1443–1448 (2015).
Alves, T. P. et al. Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis. J. Am. Soc. Nephrol. 21, 1361–1369 (2010).
Lipkowitz, M. S. et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 83, 114–120 (2013).
Parsa, A. et al. APOL1 risk variants, race, and progression of chronic kidney disease. N. Engl. J. Med. 369, 2183–2196 (2013).
Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747–753 (2009).
Gorski, M. et al. Genome-wide association study of kidney function decline in individuals of European descent. Kidney Int. 87, 1017–1029 (2015).
Okada, Y. et al. Meta-analysis identifies multiple loci associated with kidney function-related traits in East Asian populations. Nat. Genet. 44, 904–909 (2012).
Chasman, D. I. et al. Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. Hum. Mol. Genet. 21, 5329–5343 (2012).
Pattaro, C. et al. Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet. 8, e1002584 (2012).
Kottgen, A. et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat. Genet. 41, 712–717 (2009).
Kottgen, A. et al. New loci associated with kidney function and chronic kidney disease. Nat. Genet. 42, 376–384 (2010).
Chambers, J. C. et al. Genetic loci influencing kidney function and chronic kidney disease. Nat. Genet. 42, 373–375 (2010).
Basile, C. The long-term prognosis of acute kidney injury: acute renal failure as a cause of chronic kidney disease. J. Nephrol. 21, 657–662 (2008).
Venkatachalam, M. A. et al. Acute kidney injury: a springboard for progression in chronic kidney disease. Am. J. Physiol. Renal Physiol. 298, F1078–F1094 (2010).
Newman, A. B. et al. Relationship between coronary artery calcification and other measures of subclinical cardiovascular disease in older adults. Arterioscler. Thromb. Vasc. Biol. 22, 1674–1679 (2002).
Bild, D. E. et al. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 111, 1313–1320 (2005).
Lee, T. C., O'Malley, P. G., Feuerstein, I. & Taylor, A. J. The prevalence and severity of coronary artery calcification on coronary artery computed tomography in black and white subjects. J. Am. Coll. Cardiol. 41, 39–44 (2003).
Freedman, B. I. et al. The impact of ethnicity and sex on subclinical cardiovascular disease: the Diabetes Heart Study. Diabetologia 48, 2511–2518 (2005).
Carnethon, M. R. et al. Racial/ethnic differences in subclinical atherosclerosis among adults with diabetes: the multiethnic study of atherosclerosis. Diabetes Care 28, 2768–2770 (2005).
Budoff, M. J. et al. Ethnic differences of the presence and severity of coronary atherosclerosis. Atherosclerosis 187, 343–350 (2006).
Keith, T. A. 3rd. Renovascular hypertension in black patients. Hypertension 4, 438–443 (1982).
Svetkey, L. P. et al. Similar prevalence of renovascular hypertension in selected blacks and whites. Hypertension 17, 678–683 (1991).
Simon, N., Franklin, S. S., Bleifer, K. H. & Maxwell, M. H. Clinical characteristics of renovascular hypertension. JAMA 220, 1209–1218 (1972).
Wheatley, K. et al. Revascularization versus medical therapy for renal-artery stenosis. N. Engl. J. Med. 361, 1953–1962 (2009).
Cooper, C. J. et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N. Engl. J. Med. 370, 13–22 (2014).
Herrmann, S. M., Saad, A. & Textor, S. C. Management of atherosclerotic renovascular disease after Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL). Nephrol. Dial. Transplant. 30, 366–375 (2015).
Ferguson, R., Grim, C. E. & Opgenorth, T. J. A familial risk of chronic renal failure among blacks on dialysis? J. Clin. Epidemiol. 41, 1189–1196 (1988).
Freedman, B. I., Spray, B. J., Tuttle, A. B. & Buckalew, V. M. Jr. The familial risk of end-stage renal disease in African Americans. Am. J. Kidney Dis. 21, 387–393 (1993).
Freedman, B. I. et al. Familial clustering of end-stage renal disease in blacks with lupus nephritis. Am. J. Kidney Dis. 29, 729–732 (1997).
Freedman, B. I., Soucie, J. M., Stone, S. M. & Pegram, S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am. J. Kidney Dis. 34, 254–258 (1999).
Freedman, B. I., Soucie, J. M. & McClellan, W. M. Family history of end-stage renal disease among incident dialysis patients. J. Am. Soc. Nephrol. 8, 1942–1945 (1997).
Freedman, B. I. et al. Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am. J. Nephrol. 25, 529–535 (2005).
Bergman, S., Key, B. O., Kirk, K. A., Warnock, D. G. & Rostant, S. G. Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease. Am. J. Kidney Dis. 27, 341–346 (1996).
Lei, H. H., Perneger, T. V., Klag, M. J., Whelton, P. K. & Coresh, J. Familial aggregation of renal disease in a population-based case-control study. J. Am. Soc. Nephrol. 9, 1270–1276 (1998).
Bochud, M. et al. Heritability of renal function in hypertensive families of African descent in the Seychelles (Indian Ocean). Kidney Int. 67, 61–69 (2005).
Kopp, J. B. et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129–2137 (2011).
Freedman, B. I. et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 66, 390–396 (2014).
Kruzel-Davila, E., Wasser, W. G., Aviram, S. & Skorecki, K. APOL1 nephropathy: from gene to mechanisms of kidney injury. Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gfu391.
Freedman, B. I. Renal microvascular susceptibility in African American pedigrees. Transplant Proc. 25, 2423–2425 (1993).
Freedman, B. I. End-stage renal failure in African Americans: insights in kidney disease susceptibility. Nephrol. Dial. Transplant. 17, 198–200 (2002).
Scavini, M. et al. Kidney disease among the Zuni Indians: the Zuni Kidney Project. Kidney Int. 68, S126–S131 (2005).
Hughson, M. D. et al. Mesangiopathic glomerulonephritis in Zuni (New Mexico) Indians. Arch. Pathol. Lab. Med. 113, 148–157 (1989).
Qualheim, R. E., Rostand, S. G., Kirk, K. A., Rutsky, E. A. & Luke, R. G. Changing patterns of end-stage renal disease due to hypertension. Am. J. Kidney Dis. 18, 336–343 (1991).
Oliverio, M. I. et al. Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. Proc. Natl Acad. Sci. USA 95, 15496–15501 (1998).
Freedman, B. I. & Skorecki, K. Gene–gene and gene–environment interactions in apolipoprotein L1 gene-associated nephropathy. Clin. J. Am. Soc. Nephrol. 9, 2006–2013 (2014).
Rosenberg, A. Z., Naicker, S., Winkler, C. A. & Kopp, J. B. HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat. Rev. Nephrol. 11, 150–160 (2015).
Ross, M. J. Advances in the pathogenesis of HIV-associated kidney diseases. Kidney Int. 86, 266–274 (2014).
Kasembeli, A. N. et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2014050469.
Jotwani, V. et al. APOL1 genotype and glomerular and tubular kidney injury in women with HIV. Am. J. Kidney Dis. 65, 889–898 (2015).
Estrella, M. M. et al. The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status. Clin. Infect. Dis. 60, 646–652 (2015).
Madhavan, S. M. et al. APOL1 localization in normal kidney and nondiabetic kidney disease. J. Am. Soc. Nephrol. 22, 2119–2128 (2011).
Ma, L. et al. Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines. J. Am. Soc. Nephrol. 26, 339–348 (2015).
Bruggeman, L. A. et al. Plasma apolipoprotein L1 levels do not correlate with CKD. J. Am. Soc. Nephrol. 25, 634–644 (2014).
Reeves-Daniel, A. M. et al. The APOL1 gene and allograft survival after kidney transplantation. Am. J. Transplant. 11, 1025–1030 (2011).
Freedman, B. I. et al. Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. Am. J. Transplant. 15, 1615–1622 (2015).
Lee, B. T. et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am. J. Transplant. 12, 1924–1928 (2012).
Nichols, B. et al. Innate immunity pathways regulate the nephropathy gene apolipoprotein L1. Kidney Int. 87, 332–342 (2015).
Genovese, G., Friedman, D. J. & Pollak, M. R. APOL1 variants and kidney disease in people of recent African ancestry. Nat. Rev. Nephrol. 9, 240–244 (2013).
Heneghan, J. F. et al. BH3 domain-independent apolipoprotein L1 toxicity rescued by BCL2 prosurvival proteins. Am. J. Physiol. Cell Physiol. 309, C332–C347 (2015).
Cheng, D. et al. Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells. J. Lipid Res. 56, 1583–1593 (2015).
Khatua, A. K. et al. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1. Am. J. Physiol. Cell Physiol. 309, C22–C37 (2015).
Anderson, B. R. et al. In vivo modeling implicates APOL1 in nephropathy: evidence for dominant negative effects and epistasis under anemic stress. PLoS Genet. 11, e1005349 (2015).
Sampson, M. G. et al. Integrative genomics identifies novel associations with APOL1 risk genotypes in black NEPTUNE subjects. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2014111131.
The authors thank Dr Todd W. Robinson, Wake Forest School of Medicine, NC, USA, for his expert review of this manuscript before submission. The authors' work described in this Review was supported by grants from the NIH (R01 DK070941, R01 DK084149 and R01 HL56266).
The authors declare no competing financial interests.
About this article
Cite this article
Freedman, B., Cohen, A. Hypertension-attributed nephropathy: what's in a name?. Nat Rev Nephrol 12, 27–36 (2016). https://doi.org/10.1038/nrneph.2015.172
Autopsy study examining non-chronic kidney disease versus chronic kidney disease caused by hypertensive-nephrosclerosis in elderly subjects
Clinical and Experimental Nephrology (2022)
Nature Reviews Disease Primers (2020)
Long term evolution of renal function in essential hypertensive patients with no baseline proteinuria
Journal of Human Hypertension (2020)
Nature Reviews Nephrology (2019)
Nature Reviews Disease Primers (2017)